We don't put every drug on the list - quite clearly Posicor wasn't going to
be consultant only, but we always caution folk not to lead the field in
prescribing of new drugs!
A new drug, when launched in the UK, has only been used for as long as a
year in a hundred patients. It will have been used in many thousands of
patients for much shorter intervals.
The long-term safety trials are therefore carried out on 'live' patients,
hence the black triangle status of new drugs. This conundrum means, for
example, that every new NSAID has a terrific side-effect profile, because it
hasn't been used widely enough for anyone to get any side-effects.
A
> -----Original Message-----
> From: [log in to unmask]
> [mailto:[log in to unmask]]On Behalf Of Jel Coward
> Sent: 15 June 1998 23:28
> To: [log in to unmask]
> Subject: Re: Shared care prescribing
>
>
> In article <[log in to unmask]>, Andrew
> Herd <[log in to unmask]> writes
> >For interest, given that a thread on a related topic has gone on for a
> >while.
> >
> >This is the Durham HA list of drugs which should be either
> consultant only,
> >or shared care. It is about to be updated - there is a rather longer
> >document which it is part of.
>
> Yes - but where will tolcapone be on it - and where were the recent
> diabetic and cardiac poisons?
>
> TIA
>
> Cheers :)
>
> --
> Jelly Bean
>
> 'When you get fed up surfing....
> .....go find some waves'
>
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|